Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

07 oct. 2020 08h00 HE | Source: Janpix Inc.

Janpix Announces $10 Million Series B Financing to Advance STAT Protein Degrader Pipeline

CAMBRIDGE, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Janpix Inc., a biotechnology company developing monovalent small molecule protein degraders of STAT proteins as novel therapeutics, today...
15 juin 2020 08h00 HE | Source: Janpix Inc.

Potent Preclinical Antitumor Activity Demonstrated by Janpix’s Selective STAT3 & STAT5 Monovalent Degraders to be presented at the Virtual Annual Meetings of the European Hematology Association and American Association for Cancer Research (Part II)

CAMBRIDGE, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- Janpix Inc., a biotechnology company developing monovalent small molecule protein degraders as novel therapeutics, today announced the company...
12 déc. 2019 11h34 HE | Source: Janpix Inc.

Janpix, Inc. Announces Appointment of Sanford (Sandy) Zweifach as Executive Chairman to its Board of Directors

–Addition of Experienced Executive to Leadership Team– CAMBRIDGE, Mass. and MISSISSAUGA, Ontario, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Janpix, Inc., a privately-held biopharmaceutical company...